Erratum (DOI:10.1016/j.healun.2009.06.025);Alteration of Matrix Metalloproteinases in Selective Left Ventricular Adriamycin-Induced Cardiomyopathy in the Pig

Journal of Heart and Lung Transplantation

Volumn 28, Issue 10, 2009, Pages 1087-1093

  Goetzenich, Andreas ^a,b   Hatam, Nima ^a   Zernecke, Alma ^a   Weber, Christian ^a   Czarnotta, Tanja ^a   Autschbach, Rüdiger ^a   Christiansen, Stefan ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; DOXORUBICIN; GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOMYOPATHY; CELL LOSS; CELL VACUOLE; COLLAGEN DISEASE; CONTROLLED STUDY; ECHOCARDIOGRAPHY; GENE EXPRESSION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEMODYNAMICS; HISTOPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SWINE;

EID: 70349237288     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healun.2009.10.012     Document Type: Erratum

References (35)

1. Green A.E., and Rose P.G. Pegylated liposomal doxorubicin in ovarian cancer. Int J Nanomedicine 1 (2006) 229-239
2. O'Brien M.E. Single-agent treatment with pegylated liposomal doxorubicin for metastatic breast cancer. Anticancer Drugs 19 (2008) 1-7
3. Kober T., Hülsewede H., Bohlius J., and Engert A. Fourth biannual report of the Cochrane Haematological Malignancies Group. J Natl Cancer Inst 98 (2006) E1
4. Steinberg J.S., Cohen A.J., Wasserman A.G., Cohen P., and Ross A.M. Acute arrhythmogenicity of doxorubicin administration. Cancer 60 (1987) 1213-1218
5. Lefrak E.A., Pitha J., Rosenheim S., and Gottlieb J.A. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 32 (1973) 302-314
6. Von Hoff D.D., and Layard M. Risk factors for development of daunorubicin cardiotoxicity. Cancer Treat Rep 65 suppl 4 (1981) 19-23
7. Wouters K.A., Kremer L.C., Miller T.L., Herman E.H., and Lipshultz S.E. Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies. Br J Haematol 131 (2005) 561-578
8. Legha S.S., Benjamin R.S., Mackay B., et al. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med 96 (1982) 133-139
9. Lipshultz S.E., Rifai N., Dalton V.M., et al. The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl J Med 351 (2004) 145-153
10. van Dalen E.C., Caron H.N., Dickinson H.O., and Kremer L.C. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev (2008) CD003917
11. Jensen B.V., Nielsen S.L., and Skovsgaard T. Treatment with angiotensin-converting-enzyme inhibitor for epirubicin-induced dilated cardiomyopathy. Lancet 347 (1996) 297-299
12. Kalay N., Basar E., Ozdogru I., et al. Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol 48 (2006) 2258-2262
13. Caulfield J.B., and Bittner V. Cardiac matrix alterations induced by adriamycin. Am J Pathol 133 (1988) 298-305
14. Picard F., Brehm M., Fassbach M., et al. Increased cardiac mRNA expression of matrix metalloproteinase-1 (MMP-1) and its inhibitor (TIMP-1) in DCM patients. Clin Res Cardiol 95 (2006) 261-269
15. Spallarossa P., Altieri P., Garibaldi S., et al. Matrix metalloproteinase-2 and -9 are induced differently by doxorubicin in H9c2 cells: the role of MAP kinases and NAD(P)H oxidase. Cardiovasc Res 69 (2006) 736-745
16. Christiansen S., and Autschbach R. Doxorubicin in experimental and clinical heart failure. Eur J Cardiothorac Surg 30 (2006) 611-616
17. Christiansen S., Perez-Bouza A., Schälte G., Hilgers R.D., and Autschbach R. Selective left ventricular adriamycin-induced cardiomyopathy in the pig. J Heart Lung Transplant 27 (2008) 86-92
18. Devereux D.F., Thibault L., Boretos J., and Brennan M.F. The quantitative and qualitative impairment of wound healing by adriamycin. Cancer 43 (1979) 932-938
19. Kelley K.W., Curtis S.E., Marzan G.T., Karara H.M., and Anderson C.R. Body surface area of female swine. J Anim Sci 36 (1973) 927-930
20. Deschamps A.M., and Spinale F.G. Pathways of matrix metalloproteinase induction in heart failure: bioactive molecules and transcriptional regulation. Cardiovasc Res 69 (2006) 666-676
21. Li Y.Y., McTiernan C.F., and Feldman A.M. Interplay of matrix metalloproteinases, tissue inhibitors of metalloproteinases and their regulators in cardiac matrix remodeling. Cardiovasc Res 46 (2000) 214-224
22. Spinale F.G., Coker M.L., Krombach S.R., et al. Matrix metalloproteinase inhibition during the development of congestive heart failure: effects on left ventricular dimensions and function. Circ Res 85 (1999) 364-376
23. Thomas C.V., Coker M.L., Zellner J.L., Handy J.R., Crumbley A.J., and Spinale F.G. Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end-stage dilated cardiomyopathy. Circulation 97 (1998) 1708-1715
24. Spinale F.G. Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiol Rev 87 (2007) 1285-1342
25. Felkin L.E., Birks E.J., George R., Wong S., Khaghani A., Yacoub M.H., and Barton P.J. A quantitative gene expression profile of matrix metalloproteinases (MMPS) and their inhibitors (TIMPS) in the myocardium of patients with deteriorating heart failure requiring left ventricular assist device support. J Heart Lung Transplant 25 (2006) 1413-1419
26. Li Y.Y., Feldman A.M., Sun Y., and McTiernan C.F. Differential expression of tissue inhibitors of metalloproteinases in the failing human heart. Circulation 98 (1998) 1728-1734
27. Tyagi S.C., Kumar S., Voelker D.J., Reddy H.K., Janicki J.S., and Curtis J.J. Differential gene expression of extracellular matrix components in dilated cardiomyopathy. J Cell Biochem 63 (1996) 185-198
28. Gunja-Smith Z., Morales A.R., Romanelli R., and Woessner J.F. Remodeling of human myocardial collagen in idiopathic dilated cardiomyopathy. Role of metalloproteinases and pyridinoline cross-links. Am J Pathol 148 (1996) 1639-1648
29. He K.L., Dickstein M., Sabbah H.N., et al. Mechanisms of heart failure with well preserved ejection fraction in dogs following limited coronary microembolization. Cardiovasc Res 64 (2004) 72-83
30. Sanchez-Quintana D., Climent V., Garcia-Martinez V., Macias D., and Hurle J.M. Extracellular matrix arrangement in the papillary muscles of the adult rat heart. Alterations after doxorubicin administration and experimental hypertension. Basic Res Cardiol 89 (1994) 279-292
31. Bai P., Mabley J.G., Liaudet L., Virág L., Szabó C., and Pacher P. Matrix metalloproteinase activation is an early event in doxorubicin-induced cardiotoxicity. Oncol Rep 11 (2004) 505-508
32. Kizaki K., Ito R., Okada M., et al. Enhanced gene expression of myocardial matrix metalloproteinases 2 and 9 after acute treatment with doxorubicin in mice. Pharmacol Res 53 (2006) 341-346
33. Rohde L.E., Ducharme A., Arroyo L.H., et al. Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice. Circulation 99 (1999) 3063-3070
34. Spinale F.G., Coker M.L., Thomas C.V., Walker J.D., Mukherjee R., and Hebbar L. Time-dependent changes in matrix metalloproteinase activity and expression during the progression of congestive heart failure: relation to ventricular and myocyte function. Circ Res 82 (1998) 482-495
35. Heath E.I., and Grochow L.B. Clinical potential of matrix metalloprotease inhibitors in cancer therapy. Drugs 59 (2000) 1043-1055